References
- Artiva Biotherapeutics . Artiva Biotherapeutics announces agreement with Merck to evaluate combinations of NK cells with tri-specific NK-Cell engagers (2022). www.artivabio.com/artiva-biotherapeutics-announces-agreement-with-merck-to-evaluate-combinations-of-nk-cells-with-tri-specific-nk-cell-engagers/
- EdiGene . EdiGene enters research collaboration with Peking University Cancer Hospital to advance the development of targeted therapy for colorectal cancer (2022). www.edigene.com/media/101.html
- PR Newswire . WuXi advanced therapies and A*STAR announce partnership to advance cell and gene therapy in the Asia-Pacific region (2022). www.prnewswire.com/news-releases/wuxi-advanced-therapies-and-astar-announce-partnership-to-advance-cell-and-gene-therapy-in-the-asia-pacific-region-301535096.html
- Chimeric Therapeutics . Chimeric enters strategic manufacturing partnership with Wuxi Advanced Therapies (2022). https://chimerictherapeutics.com/wp-content/uploads/2022/04/Strategic-Manufacturing-Partnership-with-WuXi-ATU.pdf
- BusinessWire . Porton Advanced and Sinorda Biomedicine enter strategic collaboration to accelerate cell therapy development for solid tumors (2022). www.businesswire.com/news/home/20220425005462/en/Porton-Advanced-and-Sinorda-Biomedicine-Enter-Strategic-Collaboration-to-Accelerate-Cell-Therapy-Development-for-Solid-Tumors
- Ncardia . Quell Therapeutics and Cellistic™ enter a strategic collaboration (2022). www.ncardia.com/news/press-release-quell-therapeutics-and-cellistic-enter-a-strategic-collaboration
- Crown Biosciences . First clinical candidate developed using HUB Organoids® and high content screening targets cancer stem cells in solid tumors, published in nature cancer (2022). https://blog.crownbio.com/press/first-clinical-candidate-developed-using-hub-organoids-and-high-content-screening-targets-cancer-stem-cells-in-solid-tumors-published-in-nature-cancer
- Herpers B , EppinkB , JamesMIet al. Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors. Nat. Cancer3, 418–436 (2022).
- Akron BioProducts . Akron BioProducts announces launch of its Closed System Solutions™ line to enable seamless integration of cGMP ancillary materials in cell and gene therapy manufacturing (2022). https://akronbiotech.com/newsroom/akron-bioproducts-announces-launch-of-its-closed-system-solutions-line-to-enable-seamless-integration-of-cgmp-ancillary-materials-in-cell-and-gene-therapy-manufacturing
- Cimeio Therapeutics . Versant Ventures launches Cimeio Therapeutics with $50 million series A (2022). www.cimeio.com/2022/04/13/versant-ventures-launches-cimeio-therapeutics/
- Lineage Cell Therapeutics . Lineage announces a Fifth Cell Therapy Program: allogeneic photoreceptor transplants for the treatment of diseases which may lead to blindness (2022). https://investor.lineagecell.com/news-releases/news-release-details/lineage-announces-fifth-cell-therapy-program-allogeneic
- Lineage Cell Therapeutics . Lineage announces pipeline expansion to include auditory neuronal cell therapy for treatment of hearing loss (2022). https://investor.lineagecell.com/news-releases/news-release-details/lineage-announces-pipeline-expansion-include-auditory-neuronal
- Ncardia . Ncardia launches Cellistic, an iPSC cell therapy CDMO (2022).www.ncardia.com/news/press-release-ncardia-launches-cellistic
- Pluristyx . Pluristyx and Accelerated Biosciences announce availability of clinical-grade immune-privileged human trophoblast stem cells (hTSCs) (2022). www.pluristyx.com/news-article/pluristyx-and-accelerated-biosciences-announce-availability-of-clinical-grade-immune-privileged-human-trophoblast-stem-cells-(htscs)
- Cynata Therapeutics . Cynata advances clinical trial in diabetic foot ulcers (2022). www.cynata.com/cyp-asx-announcements
- Lineage Cell Therapeutics . Lineage and Cancer Research UK announce completion of patient enrollment in Phase I clinical study of VAC2 for the treatment of non-small-cell lung cancer (2022). https://investor.lineagecell.com/node/22311/pdf
- ClinicalTrials.gov. NCT03371485 . AST-VAC2 vaccine in patients with non-small-cell lung cancer (2022). www.clinicaltrials.gov/ct2/show/NCT03371485?term=NCT03371485
- Mustang Bio . Mustang Bio announces a Phase I clinical trial combining MB-101 (IL13Rα2‐targeted CAR T cell therapy) and MB-108 (C134 oncolytic virus) for the treatment of glioblastoma (2022). https://ir.mustangbio.com/news-events/press-releases/detail/137/mustang-bio-announces-a-phase-1-clinical-trial-combining
- ClinicalTrials.gov. NCT02208362 . Genetically modified T-cells in treating patients with recurrent or refractory malignant glioma (2022). www.clinicaltrials.gov/ct2/show/NCT02208362
- ClinicalTrials.gov. NCT03657576 . Trial of C134 in patients with recurrent GBM (C134-HSV-1) (2022). www.clinicaltrials.gov/ct2/show/NCT03657576
- PR Newswire . Isleworth Healthcare Acquisition Corp. and Cytovia Therapeutics announce agreement for business combination to create publicly listed company focused on empowering natural killer cell therapeutics to fight cancer (2020). www.prnewswire.com/news-releases/isleworth-healthcare-acquisition-corp-and-cytovia-therapeutics-announce-agreement-for-business-combination-to-create-publicly-listed-company-focused-on-empowering-natural-killer-cell-therapeutics-to-fight-cancer-301533698.html
- Caladrius Biosciiences . Caladrius Biosciences and Cend Therapeutics announce definitive merger agreement (2022). https://ir.caladrius.com/node/15941/pdf
- FUJIFILM . Fujifilm completes acquisition of a dedicated cell therapy manufacturing facility from Atara Biotherapeutics, Inc (2022). www.fujifilm.com/jp/en/news/hq/7817
- Gamida Cell . Gamida Cell announces FDA clearance of IND and removal of clinical hold for NK cell therapy candidate GDA-201 (2022). https://investors.gamida-cell.com/node/8646/pdf
- ClinicalTrials.gov. NCT05296525 . Evaluation of safety and efficacy of allo GDA-201 NK cells in patients with relapsed/refractory B Cell NHL (2022). www.clinicaltrials.gov/ct2/show/NCT05296525
- Kite Pharma . Yescarta® receives U.S. FDA approval as first CAR T-cell therapy for initial treatment of relapsed or refractory large B-cell lymphoma (LBCL) (2022). www.kitepharma.com/news/press-releases/2022/4/yescarta-receives-us-fda-approval-as-first-car-tcell-therapy-for-initial-treatment-of-relapsed-or-refractory-large-bcell-lymphoma-lbcl
- ClinicalTrials.gov. NCT03391466 . Efficacy of axicabtagene ciloleucel compared to standard of care therapy in subjects with relapsed/refractory diffuse large B cell lymphoma (ZUMA-7) (2022). www.clinicaltrials.gov/ct2/show/NCT03391466
- Kite Pharma . Kite receives U.S. FDA approval of new state-of-the-art CAR T-cell therapy manufacturing facility in Maryland (2022). www.kitepharma.com/news/press-releases/2022/4/kite-receives-us-fda-approval-of-new-stateoftheart-car-tcell-therapy-manufacturing-facility-in-maryland
- Precigen . Precigen receives fast track designation for PRGN-3006 UltraCAR-T® in patients with relapsed or refractory acute myeloid leukemia (2022). https://investors.precigen.com/node/12616/pdf
- ClinicalTrials.gov. NCT03927261 . PRGN-3006 adoptive cellular therapy for relapsed or refractory AML or high risk MDS (2022). www.clinicaltrials.gov/ct2/show/NCT03927261
- Foong P . Washington state sues ‘snake oil’ stem cell clinic. BioEdge (2022). https://bioedge.org/stem-cells/washington-state-prosecutes-snake-oil-stem-cell-clinic/
- Axol Biosciences . Axol Bioscience raises £3.2 million GBP (c. $4.2 million USD) (2022). www.axolbio.com/news/axol-bioscience-raises-3-2-million-gbp-c-4-2-million-usd
- Be Biopharma . Be Bio closes $130 million financing to pioneer engineered B cells, a new class of cellular medicines (2022). www.be.bio/blog/be-bio-closes-130-million-financing-to-pioneer-engineered-b-cells-a-new-class-of-cellular-medicines/
- BioEclipse Therapeutics . Bioeclipse Therapeutics™ awarded almost $8 million grant by California Institute For Regenerative Medicine (CIRM) to fund ongoing Phase I CRX100 Cancer Immunotherapy Clinical Trial (2022). www.bioeclipse.com/2022/04/26/bioeclipse-therapeutics-awarded-almost-8-million-grant-by-california-institute-for-regenerative-medicine-cirm-to-fund-ongoing-phase-1-crx100-cancer-immunotherapy-clinical-trial/
- ClinicalTrials.gov. NCT04282044 . Study of CRX100 in patients with advanced solid tumors (2022). www.clinicaltrials.gov/ct2/show/NCT04282044
- bluebird bio . bluebird bio initiates restructuring to reduce operating expenses and advance near-term opportunities to bring potentially curative gene therapies to patients in the US (2022). https://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-initiates-restructuring-reduce-operating-expenses